↓ Skip to main content

Simvastatin treatment does not affect serum Vitamin D concentrations in patients with dyslipidemia: A randomized double-blind placebo-controlled cross-over trial

Overview of attention for article published in International Journal of Preventive Medicine, January 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
110 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Simvastatin treatment does not affect serum Vitamin D concentrations in patients with dyslipidemia: A randomized double-blind placebo-controlled cross-over trial
Published in
International Journal of Preventive Medicine, January 2016
DOI 10.4103/2008-7802.183652
Pubmed ID
Authors

Mohsen Mazidi, Haleh Rokni, AmirHossein Sahebkar, Akram Mohammadi, Majid Ghayour-Mobarhan, GordonA Ferns

Abstract

Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events. The purpose of this study was to determine the effect of simvastatin on serum Vitamin D status in dyslipidemic patients as Vitamin D status has an impact on monocyte/macrophage function and may also contribute to cardiovascular risk. Selected individuals (n = 102) were treated with simvastatin (40 mg/day), or matching placebo in a randomized, double-blind, placebo-controlled, crossover trial. Each treatment period (with simvastatin or placebo) lasted for 30 days and was separated by a 2-week washout phase. Serum Vitamin D concentration was assessed pre- and post-treatment. Seventy-seven completed the trial, noncompliance with the study protocol and drug intolerance or relocation were the causes for drop-out. No significant carry-over effect was observed for the assessed parameters. There was a reduction in the serum levels of low-density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), and triglycerides (P < 0.05). Nevertheless, simvastatin therapy did not significantly affect serum level of high-density lipoprotein cholesterol and Vitamin D level (P > 0.05). Short-term treatment with simvastatin (40 mg/day) does not have a significant affect on serum levels of Vitamin D.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Unknown 109 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 16%
Student > Bachelor 16 15%
Student > Ph. D. Student 12 11%
Researcher 8 7%
Student > Doctoral Student 5 5%
Other 15 14%
Unknown 36 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 8%
Engineering 7 6%
Agricultural and Biological Sciences 6 5%
Medicine and Dentistry 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 33 30%
Unknown 45 41%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2016.
All research outputs
#12,135,542
of 15,261,320 outputs
Outputs from International Journal of Preventive Medicine
#310
of 449 outputs
Outputs of similar age
#184,688
of 263,658 outputs
Outputs of similar age from International Journal of Preventive Medicine
#1
of 1 outputs
Altmetric has tracked 15,261,320 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 449 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.9. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,658 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them